Rivastigmine Transdermal System
These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000
Approved
Approval ID
82630f84-fb47-47ab-8ee2-1720a486de02
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Oct 20, 2023
Manufacturers
FDA
Bryant Ranch Prepack
DUNS: 171714327
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Rivastigmine
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code63629-2065
Application NumberANDA209063
Product Classification
M
Marketing Category
C73584
G
Generic Name
Rivastigmine
Product Specifications
Route of AdministrationTRANSDERMAL
Effective DateDecember 20, 2021
FDA Product Classification
INGREDIENTS (1)
RIVASTIGMINEActive
Quantity: 4.6 mg in 24 h
Code: PKI06M3IW0
Classification: ACTIB